Anti-EpCAM monoclonal antibody K931

Drug Profile

Anti-EpCAM monoclonal antibody K931

Alternative Names: Anti-EpCAM monoclonal antibody - Wilex; K 931; WX K931

Latest Information Update: 29 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VU University Medical Center
  • Developer Wilex
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 May 2003 Anti-EpCAM monoclonal antibody K931 has been exclusively licensed to Wilex for the treatment of advanced solid cancers
  • 15 May 2003 Preclinical development for Solid tumours in Germany (unspecified route)
  • 15 May 2003 Preclinical development for Solid tumours in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top